IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Compliance With Once Daily Glaucoma Medication
This study has been completed.
Sponsor:
Alcon Research
Collaborators:
Johns Hopkins University
University of Pennsylvania
Information provided by (Responsible Party):
Alcon Research
ClinicalTrials.gov Identifier:
NCT00333463
First received: June 1, 2006
Last updated: November 17, 2016
Last verified: March 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A study to examine patient compliance with once daily glaucoma medication
| Condition | Intervention |
|---|---|
| Compliance | Behavioral: Intervention |
| Study Type: | Observational |
| Study Design: | Time Perspective: Retrospective |
| Official Title: | Compliance With Once Daily Glaucoma Medication |
Resource links provided by NLM:
Genetics Home Reference related topics:
early-onset glaucoma
MedlinePlus related topics:
Glaucoma
U.S. FDA Resources
Further study details as provided by Alcon Research:
| Estimated Enrollment: | 700 |
| Study Start Date: | June 2006 |
| Study Completion Date: | September 2007 |
| Primary Completion Date: | September 2007 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Intervention group
The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices.
|
Behavioral: Intervention
The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices.
|
|
Non-Intervention Group
The control group was told to take drops as prescribed and received no additional intervention.
|
Eligibility| Ages Eligible for Study: | Child, Adult, Senior |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
Primary open angle glaucoma or ocular hypertension patients
Criteria
Inclusion Criteria:
- Primary open angle glaucoma or ocular hypertension patients
Exclusion Criteria:
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00333463
Please refer to this study by its ClinicalTrials.gov identifier: NCT00333463
Locations
| United States, Texas | |
| Ft. Worth | |
| Ft. Worth, Texas, United States, 76134 | |
Sponsors and Collaborators
Alcon Research
Johns Hopkins University
University of Pennsylvania
Investigators
| Study Director: | David Friedman, MD | Study Director |
More Information
Publications:
| Responsible Party: | Alcon Research |
| ClinicalTrials.gov Identifier: | NCT00333463 History of Changes |
| Other Study ID Numbers: |
CMS-06-03 |
| Study First Received: | June 1, 2006 |
| Last Updated: | November 17, 2016 |
Additional relevant MeSH terms:
|
Glaucoma Ocular Hypertension Eye Diseases |
ClinicalTrials.gov processed this record on July 25, 2017